Clinical trial
Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00358163 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00358163 |
|---|---|
| Title | Trial of PTK787/ZK 222584 Plus Paclitaxel |
| Official title | Phase I Study of the Oral Vascular Endothelial Growth Factor Inhibitor PTK787/ZK 222584 in Combination With Paclitaxel in Patients With Advanced Solid Tumors. |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Novartis Pharmaceuticals Industry Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Non-hematologic Malignancies |
| Intervention type | Drug |
| Interventions | PTK787/ZK 222584, paclitaxel |
| Enrollment | 7 |
| Start date | Apr 26, 2006 |
| Primary completion | May 29, 2008 |
| Completion | May 29, 2008 |
| First posted | Jul 31, 2006 |
| Last update posted | Apr 29, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: